Boaz Kurtis

Boaz Kurtis is the Chief Executive Officer of Intersect Diagnostics, which he founded to fill unmet needs in translational medicine and drug development programs. As a molecular pathologist, Boaz’s strategic focus for Intersect is to advance applications of novel technologies that integrate digitized histopathology with quantifiable proteomic and genomic biomarker assessment. Prior to founding Intersect, Boaz held roles of increasing responsibility at Cancer Genetics, Inc. (NASDAQ: CGIX), serving most recently as Vice President for Molecular Pathology. In that capacity, he led the company’s molecular diagnostics program for the biopharma & biotech industry in part by integrating next-generation sequencing data with immunohistochemistry. Earlier in his career, Boaz spent five years training cardiac electrophysiologists on 3-D electroanatomic mapping for Biosense Webster, Inc. (a Johnson & Johnson Company), the world’s leading manufacturer of heart rhythm mapping and navigation systems. Boaz holds a BA in History from the University of Maryland and an MD from Sackler School of Medicine of Tel-Aviv University.